RxDoctor Payments Data

Umar Shuaib, MD

Neurology · Cleveland, OHNPI 1477950343

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,000 of the $10,657 with a category attached, or 93.8%. Abbott accounts for 94.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $10,016 and has fallen 97.8% since, to $221 in 2025.

$10,657in general payments, 2019–2025

Across 11 payments — averaging $968.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Acorda Therapeutics, Inc$203
  • Insightec,inc$198
  • Medtronic$186
  • AbbVie$24
  • Boston Scientific$16
$92,031in research payments, 2019–2025

Across 1 payment — averaging $92,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$92K

What the payments were for

  • Grants$10,00094%
  • Food & beverage$6576%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott3$10,031
Acorda Therapeutics, Inc2$203
Insightec,inc2$198
Medtronic2$186
AbbVie1$24
Boston Scientific1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,657 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024
$67,907
Medicare patients
313
Services billed
913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$192,815
AustedoDeutetrabenazine30$180,319
RytaryCarbidopa/Levodopa39$86,951
Carbidopa47$18,643
Carbidopa-LevodopaCarbidopa/Levodopa607$16,372
Entacapone44$6,437
Carbidopa-Levodopa ErCarbidopa/Levodopa56$3,873
Primidone118$2,176
AmantadineAmantadine Hcl57$1,952
Gabapentin119$1,808
Ropinirole Hcl60$1,647
Midodrine Hcl18$1,427
Tizanidine Hcl19$1,146
Venlafaxine Hcl ErVenlafaxine Hcl31$1,037
Propranolol Hcl ErPropranolol Hcl38$867

Paid to pharmacies, not to this prescriber.

Other neurology in Cleveland

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →